Protein marker and method for screening drug anaphylactoid reaction susceptive groups

An allergic reaction and protein labeling technology, applied in the field of molecular biology, can solve the problems of not detecting the risk of anaphylactic reaction in patients in advance, not monitoring anaphylactic reaction, inapplicability, etc., to improve safety, high sensitivity and specificity. , easy to use effect

Inactive Publication Date: 2018-02-16
XI AN JIAOTONG UNIV
View PDF2 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is currently no corresponding standard for monitoring anaphylactoid reactions clinically, and there is no relevant research on early detection of patients' r

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Protein marker and method for screening drug anaphylactoid reaction susceptive groups
  • Protein marker and method for screening drug anaphylactoid reaction susceptive groups
  • Protein marker and method for screening drug anaphylactoid reaction susceptive groups

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] The determination of the expression level of characteristic protein markers in normal population includes the following steps:

[0039] 1) Collect peripheral blood samples from 15 test subjects who did not experience clinical anaphylaxis, and collect 1.5-2mL peripheral blood for each sample.

[0040] 2) Use the finished ELASA kit (Human Mas-Related G-Protein Coupled ReceptorMember X2 (MRGPRX2) ELISA Kit) (Cat. No: MBS9333336) method to detect the expression level of MRGPRX2 protein.

[0041] 3) In 15 samples, the maximum value of MRGPRX2 protein expression was 14.43ng / mL, and the minimum value was 12.15ng / mL.

Embodiment 2

[0042] Example 2 Determination of the expression level of characteristic protein markers in allergic populations, including the following steps:

[0043] 1) Collect peripheral blood samples from 15 test subjects who were clinically confirmed to have anaphylactoid reactions, and collect 1.5-2 mL of peripheral blood for each sample.

[0044] 2) Use the finished ELASA kit (Human Mas-Related G-Protein Coupled ReceptorMember X2 (MRGPRX2) ELISA Kit) (Cat. No: MBS9333336) method to detect the expression level of MRGPRX2 protein.

[0045] 3) Among the 15 samples, the maximum value of MRGPRX2 protein expression was 25.65ng / mL, and the minimum value was 20.58ng / mL.

[0046] The measurement results according to Example 1 and Example 2 are shown in figure 2 in, according to figure 2 It can be clearly seen that the expression level of peripheral blood MRGPRX2 protein in the testers with anaphylaxis (Positive) was significantly higher than that in the testers without anaphylaxis (Negati...

Embodiment 3

[0055] Using Western-Blot to verify the expression of the characteristic protein marker MRGPRX2 protein in the allergic population and the normal population, including the following steps:

[0056] 1) Extract the total protein in the blood of allergic people and normal people, and use the BCA protein quantification kit (Bebo Bio BB-3401-500T) to determine the amount of protein loaded.

[0057] 2) Western-Blot SDS-PAGE Kit (PIONEER; WBO1) was used to detect the relative expression of MRGPRX2 protein in the allergic population and the normal population. The experimental results are shown in Picture 1-1 with Figure 1-2 in, especially according to Figure 1-2 It can be clearly seen from the results that, compared with the normal population (low), the relative expression of MRGPRX2 protein in the peripheral blood of the drug-like hypersensitivity population (high) is significantly increased, which is consistent with the results of the ELASA experiment.

[0058] Western-Blot was...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Expressionaaaaaaaaaa
Expressionaaaaaaaaaa
Login to view more

Abstract

The invention provides an MRGPRX2 protein serving as a protein marker for screening drug anaphylactoid reaction susceptive groups and application thereof. Researches find out that the relative expression of the MRGPRX2 protein in peripheral blood has relevance to drug anaphylactoid reaction susceptivity of testers, and the MRGPRX2 protein can serve as a protein marker for screening the drug anaphylactoid reaction susceptive groups. The relative expression of the MRGPRX2 protein is used for evaluating risk of anaphylactoid reaction of patients occurring in the medication process, and has significance on clinical guiding of pharmacy safety. The method for screening drug anaphylactoid reaction susceptive groups provided by the invention is used for screening occurrence risk of anaphylactoid reaction of the patients and has extremely high susceptivity and specificity. Moreover, since the clinically available peripheral blood is adopted for detection, the method is convenient to use and issuitable for screening of large scale population of patients before medication, advanced discovery of the anaphylactoid reaction susceptive groups is facilitated, and the medication safety is improved.

Description

technical field [0001] The invention relates to the technical field of molecular biology, in particular to a protein marker and a method for screening people sensitive to drug-like allergic reactions. Background technique [0002] Drug-induced allergic reactions are mainly divided into type I (immediate), type II (cytotoxic), type III (immune complex type), type IV (delayed) anaphylaxis and pseudoanaphylaxis. The clinical symptoms of anaphylactoid reactions are similar to anaphylaxis. But the mechanism of its reaction is not the same as type I allergic reaction. When the drug enters the body, it can directly cause mast cells to release their contents, triggering an allergic reaction, and the clinical symptoms are severe. Anaphylactic shock occurs in a very small number of individuals who receive therapeutic doses of drugs. There is no sensitization process, and the serum IgE concentration of the patients does not increase, but they show typical symptoms of immediate allerg...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): G01N33/68C07K14/705
CPCG01N33/68C07K14/705G01N2333/705
Inventor 贺浪冲张涛贺怀贞丁园园车德路
Owner XI AN JIAOTONG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap